CYTEGRITY
Live / Applied — First extension granted (statement of use) (as of 08 Dec 2025)
What this means for you
Not registered yet, but its 20 Oct 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98232780
- Mark type
- Stylized text
- Filed
- 20 Oct 2023
- Published for opposition
- 13 May 2025
- Attorney of record
- Scott D. Woldow
Goods and services
- Class 035 — Advertising and business services: Business consultation in the field of business process improvement for clinical manufacturing
- Class 040 — Treatment of materials: Biomanufacturing for others, namely, manufacturing of pharmaceuticals and of viral vectors and gene therapy vectors using biological organisms or viruses in the manufacturing process; custom manufacturing services of ex vivo, lentiviral stable cell lines; custom manufacturing services of lentiviral vectors by transient transfection; Biomanufacturing for others, namely, manufacturing of viral vectors and gene therapy vectors using biological organisms or viruses in the manufacturing process; biomanufacturing for others, namely, manufacturing of cell lines and cells using biological organisms or viruses in the manufacturing process; biomanufacturing for others, namely, manufacturing of biological preparations for use in industry and science, and cell cultures for medical purposes using biological organisms or viruses in the manufacturing process; Biomanufacturing process consulting
- Class 042 — Scientific and technological services: Scientific and pharmaceutical research and development; medical research; biological research; Scientific laboratory services in in the field of viral vectors and gene therapy vectors; Scientific, pharmaceutical, and medical research in the field of bioproduction, regulatory pathway services, accessory proteins and alternative envelope proteins; Scientific research consulting in the field of clinical manufacturing
- Class 045 — Legal and security services: Regulatory compliance consulting in the field of clinical manufacturing
Owner
- CSL Behring Gene Therapy, Inc., Pasadena, CA, US
- CSL Behring Gene Therapy, Inc., Pasadena, CA, US
Prosecution history
- 08 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Dec 2025 — SOU EXTENSION 1 GRANTED
- 08 Dec 2025 — SOU EXTENSION 1 FILED
- 08 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 25 Aug 2025 — ASSIGNED TO EXAMINER
- 08 Jul 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 13 May 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 13 May 2025 — PUBLISHED FOR OPPOSITION
- 07 May 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 15 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 14 Apr 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 14 Apr 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 14 Apr 2025 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 14 Jan 2025 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 14 Jan 2025 — FINAL REFUSAL E-MAILED